This webinar spotlighted the latest capabilities from Our Future Health, the UK’s largest health research programme, now offering imputed and geographic data, dispensed medication records, and direct participant recruitment pathways.
Scancell Holdings, the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC).
Brainomix has published a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment.
The Functional Genomics Screening Laboratory, based at the Milner Therapeutics Institute, has won an OBN Award in the category of Most Impactful Industry Collaboration.
GLP-1 collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.
Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.
